The 3-hydoxy -3-methylglutaryl coenzyme A reductase inhibitors (statins) have been shown to improve multiple normal endothelial cell functions and inhibit vascular wall cell proliferation. We hypothesized that one such agent, simvastatin, would attenuate chronic hypoxic pulmonary hypertension. Male adult Sprague-Dawley rats were exposed protein expression in the HS group was less than H (P < 0.01), but was similar in N vs.
Introduction
Chronic pulmonary hypertension is characterized by a component of abnormal pulmonary vasoconstriction and by structural remodeling of the small pulmonary arteries.
Both processes lead to a progressive increase in pulmonary vascular resistance, which when extreme, culminates in right ventricular failure and death. The syndrome occurs in diverse clinical settings, including lung disease associated with alveolar hypoxia.
Endothelial cell injury/dysfunction is considered to be a key factor in the pathogenesis of pulmonary hypertension (3), leading to increased vascular smooth muscle tone, cell proliferation in the vascular wall and activation of thrombotic mechanisms, all of which participate in the process of remodeling. Currently available therapies have a beneficial clinical effect, yet cannot reverse the disease process. Therefore, the response is variable with considerable morbidity and mortality despite therapy (33) . Clearly, there is an urgent need for new therapies.
The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have been shown to exert numerous effects on vascular wall function, independent of their cholesterol lowering effect, that would be expected to have a beneficial impact on the remodeling of pulmonary hypertension (44) . For example, statins upregulate endothelial nitric oxide synthase (eNOS) expression and activity (13), increase prostacyclin (40) and reduce endothelin production by endothelial cells (20) . Statins are also potent inhibitors of vascular smooth muscle cell growth (30) , a prominent feature of human and experimental pulmonary hypertension (10). Many of these actions are a consequence of inhibiting mevalonate synthesis. The latter is the precursor of not only R1 4 cholesterol, but also isoprenoid intermediates required for the activity of Rho and other small G-proteins (44) .
To determine the possible utility of statin therapy in pulmonary hypertension, we tested the ability of simvastatin to attenuate pulmonary hypertension and pulmonary vascular remodeling in a rat model of chronic hypoxia-induced pulmonary hypertension. We also explored the potential mechanism by assessing the effect of treatment on lung expression of eNOS.
Materials and Methods

Experimental Animals and Treatment
Male adult Sprague-Dawley rats (Hilltop Lab Animals, Scottsdale, PA) weighing between 150 -250 gm were utilized. All animal care and procedures were performed in accordance with institutional guidelines. Four groups of rats were studied: normoxic controls (n = 7), hypoxic controls (n = 8), normoxic simvastatin-treated (n = 8) and 
Assessment of Pulmonary Hypertension
After 14 days, the animals were removed from their respective chambers and anesthetized with an intraperitoneal injection of xylazine (10 mg/kg) and ketamine (100 mg/kg). A tracheal cannula was then inserted and the animals ventilated with room air with Harvard rodent ventilator model 683 (Harvard Apparatus, South Natick, MA) set a rate of 90 breaths/min and tidal volume of 8 ml/kg body weight. To measure pulmonary arterial pressure, the chest of the rat was opened via a midline incision. An 18-gauge catheter filled with heparinized saline was inserted through the wall of the right ventricle and advanced into the pulmonary artery. Pressure in the pulmonary artery was measured with a Datascope 2001A (Datascope, Paramus, NJ). A 3 ml sample of blood was drawn from the left ventricle into EDTA tubes for measurement of hematocrit by centrifugation.
The rats were then sacrificed by exsanguination and the heart and lungs removed en bloc. 
Immunohistochemistry and Vascular Morphology
The remainder of the lung was then inflated by tracheal infusion of 5 ml of paraformaldehyde (4% wt/vol) in 0.1 M PBS (pH 7.4). The lung was fixed for 2 hr and 3-4 sagital slices obtained, cutting parallel to the hila. The lung slices were then washed in PBS and stored in 70% ethanol. Six µm thick paraffin sections were then mounted on precleaned glass slides. Lung sections were stained with hematoxylin and eosin and monoclonal α-smooth muscle actin antibody (1:100, Sigma, St. Louis, MO) as previously 
Lung eNOS
Western blotting for eNOS was performed on whole lung homogenates as previously described (12) from 6 animals in each group. Briefly, lung homogenates (50 µg of protein/rat) were separated under denaturing conditions in a 4 -20% linear gradient SDS- 
Statistical Analysis
Data are expressed as means ± SE. Comparisons between groups was performed with one-way ANOVA and Dunnett's method for post-hoc multiple comparisons assuming unequal variances using SPSS software (Chicago, IL). Comparison of percent medial wall thickness between the hypoxia and hypoxia/simvastatin-treated groups was performed with an independent samples T-test. A P value less than 0.05 was considered significant.
Results
Effect of Simvastatin on Hemodynamic Parameters
The normoxic group gained 127 ± 12 gm during the 14-day experiment; whereas the normoxic simvastatin-treated and hypoxic control groups only gained 58 ± 8 gm and 48 ± 2 gm, respectively (P < 0.01 for either group compared with normoxia). The hypoxic simvastatin-treated animals had a minimal weight gain of 12 ± 7 gm (P < 0.01 compared with hypoxia alone). No differences were observed in pulmonary artery pressure, relative right ventricular weight or hematocrit between normoxia and normoxia/simvastatintreated animals (Figures 1 -3 ). Mean pulmonary artery pressure (mPAP) and relative right ventricular weight more than doubled in hypoxic animals compared with normoxic controls (Figures 1, 2 ). Simvastatin treatment reduced this increase in both mPAP and RV/(LV+S) by more than 50%. As expected, hematocrit was higher in the hypoxic group compared with normoxia. Surprisingly, simvastatin treatment essentially abolished the polycythemic response to hypoxia ( Figure 3 ).
Effect of Simvastatin on Vascular Morphology
The alveolar vessels in normoxic animals showed scant staining on smooth muscle α-actin antibody immunostained sections. No differences in vascular morphology were observed between normoxic controls and normoxic/simvastatin-treated rats. In hypoxiatreated animals, there were significant increases in muscularized vessels (Table 1) .
Treatment with simvastatin was associated with a marked reduction in the muscularization of these arteries induced by hypoxia (Table 1 
Effect of Simvastatin on Lung eNOS
Western blotting of lung homogenates revealed the anticipated increase in eNOS expression induced by hypoxia. No difference in eNOS expression was observed between normoxic controls and normoxia/simvastatin-treated animals. Interestingly, simvastatin treatment attenuated the hypoxic upregulation of eNOS protein ( Figure 5 ).
Discussion
The HMG Co-A reductase inhibitors, statins, have had a dramatic impact on clinical outcomes in patients with coronary artery disease. Several studies have documented benefits unrelated to cholesterol lowering (7;19) with multiple "pleiotropic" effects on vascular wall function that would be expected to attenuate vascular remodeling (44) .
These effects stem from their ability to reduce the production of the isoprenoid intermediates, farnesyl and geranylgeranyl pyrophosphate, compounds which are distal to mevalonate in the cholesterol synthetic pathway. These lipophilic molecules are then covalently bound to Rho and other small G-proteins in a post-translational modification that is essential for attachment of these important signaling proteins to cell membranes and regulators and for their activation of downstream effectors (43) .
In this study, we examined the hypothesis that statin treatment could attenuate pulmonary Statins have been shown to increase eNOS expression in systemic endothelial cells in vitro (29) and in the systemic circulation of mice (1) . Surprisingly, statin treatment in the present study actually decreased eNOS expression in whole lung homogenates of chronically hypoxic rats to levels similar to normoxic controls. No effect of simvastatin treatment on lung eNOS protein levels was observed in normoxic animals. Thus, enhanced lung eNOS expression does not appear to account for the attenuation of pulmonary hypertension in our study. Chronic hypoxia is known to increase lung eNOS expression in rats. While some authors contend that it is hypoxia per se which induces eNOS expression (12;31), others have provided evidence supporting a more important role for hemodynamic factors (4;38). If the latter is the case, the lower pulmonary artery pressure and/or blood viscosity (from lower hematocrit) in the hypoxia plus simvastatin group could have accounted for decreased eNOS expression compared with hypoxia alone. In the study by Nishimura et al, simvastatin treatment was associated with restoration of the reduced eNOS expression observed with monocrotaline plus pneumonectomy (37). While it is clear that chronic hypoxic pulmonary hypertension is associated with increased eNOS expression in rats, the effect of chronic hypoxia on lung eNOS activity is controversial (17) . A recent study by Murata and colleagues studied eNOS activity in isolated pulmonary artery obtained at one week in chronically hypoxic, hypertensive rats (35). Using a fluorescence microscopic technique to directly visualize the endothelium in situ, the authors demonstrated markedly reduced carbachol-induced endothelial NO production in hypoxic segments compared with normoxia, indicating impaired eNOS enzyme activity. They also showed that eNOS was more tightly coupled with caveolin-1 (a negative regulator of eNOS activity) and was dissociated from HSP-90 Additional studies are required to characterize the effects of simvastatin on lung NOS activity in this model.
One potentially important confounder in our study was the unexpected reduction in hematocrit in the simvastatin-hypoxia group, as this effect could partially explain the lower pulmonary artery pressure and right ventricular hypertrophy. Polycythemia and the consequent increase in blood viscosity is an important determinant of the increased pulmonary vascular resistance in response to chronic hypoxia. In chronically hypoxic rats phlebotomized to normocythemia after hypoxia exposure, pulmonary artery pressure and pulmonary vascular resistance were reduced in comparison to control hypoxic animals, but remained higher than normoxic controls (14) . Hepatocellular injury is a recognized toxicity of statins (15), but is not generally observed at the dose employed in this study. We examined the liver of one of the hypoxia/simvastatin-treated animals and failed to observe any histologic abnormalities.
Simvastatin may have somehow interfered with the polycythemic response to hypoxia.
This response is mediated through activation of hypoxia-inducible factor-1α (HIF-1α), which subsequently induces erythropoietin expression (25). Generation of reactive oxygen species during hypoxia stabilizes HIF-1α protein, allowing it to accumulate (8).
The anti-oxidant effect of statins would be expected to suppress reactive oxygen species generation during hypoxia and could thereby reduce HIF-1α accumulation. In addition,
Rac and Ras, two small G-proteins that require isoprenylation for their activity, are involved in the erythropoietin signal transduction pathway in hematopoietic cells (2) .
Other agents that have been shown to attenuate chronic hypoxic pulmonary hypertension in rats have also suppressed the polycythemic response (18;34).
In summary, we have shown that treatment with simvastatin significantly attenuates pulmonary hypertension, polycythemia and pulmonary vascular remodeling in chronically hypoxic rats. Enhancement of lung eNOS expression does not appear to be involved in mediating this effect. Further studies are required to confirm our findings and delineate the mechanism(s). Statins may prove to be a useful adjunct to currently available therapies for pulmonary hypertension. each of the other groups. P < 0.01 for hypoxia + simvastatin vs. normoxia and normoxia + simvastatin. P not significant for normoxia vs. normoxia + simvastatin. Figure 5B 
